GSC
PPBT

Ground Swell Capital’s Purple Biotech PPBT Stock Holding History

Ground Swell Capital’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-74
Closed -$20.3K – 99
2022
Q4 		$20.3K Buy
+74
New +$28.4K 0.09% 55

Other funds holding PPBT

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return
WAOI
Wealth Advisors of Iowa West Des Moines, Iowa $369M AUM 18.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Ground Swell Capital's PPBT Position: Q1 2023 in Review

Ground Swell Capital sold out of Purple Biotech (PPBT) in Q1 2023, closing a stake of 74 shares — an estimated $20.3K sold.

Ground Swell Capital first reported a position in PPBT in Q4 2022 and held it in 1 quarter. The position peaked at $20.3K in Q4 2022. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2023.

  • Ground Swell Capital reported no remaining Purple Biotech position as of Q1 2023 after selling out during the quarter.
  • Ground Swell Capital sold 74 Purple Biotech shares in Q1 2023, an estimated $20.3K.
  • Ground Swell Capital first reported a position in Purple Biotech in Q4 2022 and held it in 1 quarter.
  • Ground Swell Capital's Purple Biotech position peaked at $20.3K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2023.

Based on Ground Swell Capital's 13F filing for Q1 2023, filed 8 May 2023.